We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.65B
1-Year Est. Return
203.21%
This Fund
S&P 500
This Quarter
Est. Return
+26.49%
1 Year Est. Return
+203.21%
3 Year Est. Return
+364.25%
5 Year Est. Return
+595.91%
10 Year Est. Return
+10,683%
AUM
$988M
AUM Growth
+$129M
(+15%)
Cap. Flow
+$16.3M
Cap. Flow
% of AUM
1.65%
Top 10 Holdings %
Top 10 Hldgs %
50.06%
Holding
77
New
6
Increased
26
Reduced
14
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$29.2M |
| 2 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$8.2M |
| 3 |
Direxion Daily S&P Biotech Bull 3X ETF
LABU
|
+$7.86M |
| 4 |
Transmedics
TMDX
|
+$6.69M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$5.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prothena Corp
PRTA
|
+$12.6M |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$10.6M |
| 3 |
Krystal Biotech
KRYS
|
+$7.45M |
| 4 |
Codexis
CDXS
|
+$7.17M |
| 5 |
CareDx
CDNA
|
+$4.87M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.36% |
| 2 | Communication Services | 9.04% |
| 3 | Miscellaneous | 0.61% |
| 4 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Prothena Corp
PRTA
$428M
| $93.3M | 9.44% |
1,538,678
-399,505
| -21% | -$12.6M |
|
|
MODN
2
DELISTED
MODEL N, INC.
MODN
| $89.3M | 9.04% |
2,608,221
-145,537
| -5% | -$4.21M |
|
3
AtriCure
ATRC
$2.86B
| $58.4M | 5.91% |
1,494,655
+15,029
| +1% | +$688K |
|
|
SPNE
4
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $40.1M | 4.06% |
7,067,572
+37,263
| +0.5% | +$237K |
|
|
KRTX
5
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $37.4M | 3.79% |
166,316
+40,523
| +32% | +$8.2M |
|
6
Halozyme
HALO
$12.1B
| $36.9M | 3.73% |
932,244
-9,001
| -1% | -$398K |
|
7
SI-BONE Inc
SIBN
$831M
| $35.4M | 3.58% |
2,027,963
+21,659
| +1% | +$346K |
|
|
CUTR
8
DELISTED
Cutera, Inc.
CUTR
| $34.8M | 3.52% |
763,180
-8,634
| -1% | -$394K |
|
9
Axogen
AXGN
$2.42B
| $34.7M | 3.51% |
2,911,824
-113,295
| -4% | -$1.13M |
|
|
10
Krystal Biotech
KRYS
$9.97B
| $34.3M | 3.47% |
492,555
-103,057
| -17% | -$7.45M |
|
11
Omnicell
OMCL
$1.49B
| $30.4M | 3.07% |
349,106
+2,077
| +0.6% | +$218K |
|
|
RETA
12
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $26.5M | 2.68% |
+1,054,985
| New | +$29.2M |
|
|
CRNX
13
DELISTED
Crinetics Pharmaceuticals
CRNX
| $26.4M | 2.68% |
1,346,652
+106,043
| +9% | +$2.16M |
|
14
Alphatec Holdings
ATEC
$1.65B
| $26M | 2.63% |
2,974,658
+49,694
| +2% | +$393K |
|
|
BLU
15
DELISTED
BELLUS Health Inc.
BLU
| $25.2M | 2.55% |
2,381,857
-26,217
| -1% | -$279K |
|
16
NeoGenomics
NEO
$2.43B
| $23.4M | 2.37% |
2,720,099
+4,612
| +0.2% | +$45.8K |
|
17
Tandem Diabetes Care
TNDM
$1.13B
| $23.2M | 2.35% |
485,620
+18,065
| +4% | +$990K |
|
18
Keros Therapeutics
KROS
$221M
| $22.5M | 2.28% |
598,213
-120
| -0% | -$4.16K |
|
|
AXNX
19
DELISTED
Axonics, Inc. Common Stock
AXNX
| $22.3M | 2.26% |
316,809
+2,805
| +0.9% | +$193K |
|
|
FNA
20
DELISTED
Paragon 28, Inc.
FNA
| $22.1M | 2.23% |
1,238,055
+544
| +0% | +$10K |
|
21
Pliant Therapeutics
PLRX
$69.4M
| $20.2M | 2.04% |
965,114
+195,744
| +25% | +$3.75M |
|
22
Ultragenyx Pharmaceutical
RARE
$1.29B
| $18.8M | 1.9% |
453,794
+1,324
| +0.3% | +$68K |
|
|
BCYC
23
Bicycle Therapeutics
BCYC
$257M
| $16.4M | 1.66% |
704,721
+439
| +0.1% | +$10.4K |
|
24
Insmed
INSM
$26.2B
| $16.3M | 1.65% |
756,417
-5,765
| -0.8% | -$138K |
|
25
OrthoPediatrics
KIDS
$607M
| $14.2M | 1.44% |
308,728
-5,996
| -2% | -$294K |
|
Similar funds
AAM
NPA
SOS
BCM
BFO
AAG
MCIL
TIM
First Light Asset Management's Q3 2022 Portfolio in Review
As of Q3 2022, First Light Asset Management held 77 positions worth $988M, up 15% from $859M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
First Light Asset Management's Q3 2022 filing shows 6 new, 26 increased, 14 reduced and 6 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 1,054,985 shares worth $26.5M. The largest sale was Prothena Corp, an estimated $12.6M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Communication Services and Miscellaneous.
- First Light Asset Management's largest Q3 2022 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 1,054,985 shares worth $26.5M.
- First Light Asset Management added most to Karuna Therapeutics, Inc. Common Stock in Q3 2022, an estimated $8.2M increase.
- First Light Asset Management's biggest Q3 2022 reduction was Prothena Corp, cutting an estimated $12.6M.
- First Light Asset Management fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $10.6M.
- First Light Asset Management's ten largest holdings make up 50% of its $988M portfolio in Q3 2022.
- First Light Asset Management opened 6 new positions and closed 6 in Q3 2022.
- First Light Asset Management's portfolio value rose 15% quarter-over-quarter to $988M.
Based on First Light Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.